Elise Haddad

Clinical trials

• A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

  Principal investigator · Recruiting · Phase 1

  M.D. Anderson Cancer Center

  2026–2031
• Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

  Principal investigator · Recruiting · Phase 1, Phase 2

  National Cancer Institute (NCI)

  2026–2027
• A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

  Principal investigator · Recruiting · Phase 1

  M.D. Anderson Cancer Center

  2024–2031
• STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

  Site PI · Recruiting · Phase 1, Phase 2

  STORM Therapeutics LTD

  2025–2028